Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
208.9 USD | +3.18% | +7.47% | -19.27% |
04-26 | Guggenheim Adjusts Price Target on Biogen to $255 From $275 | MT |
04-25 | Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRA | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- With an enterprise value anticipated at 3.49 times the sales for the current fiscal year, the company turns out to be overvalued.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-19.27% | 30.42B | B- | ||
-4.66% | 86.13B | A- | ||
+1.32% | 39.82B | A- | ||
+57.86% | 25.23B | A | ||
-16.09% | 15.36B | C | ||
-9.14% | 11.95B | D+ | ||
-17.69% | 11.6B | B- | ||
-43.00% | 11.51B | B | ||
+5.24% | 8.71B | B+ | ||
-8.42% | 8.12B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BIIB Stock
- Ratings Biogen Inc.